Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Ohri, Nitin; Piperdi, Bilal; Garg, Madhur K.; Bodner, William R.; Gucalp, Rasim; Perez-Soler, Roman; Keller, Steven M.; Guha, Chandan
• Is Part Of: Lung cancer. Volume 87:Issue 1(2015:Jan.)
• Page Start: 23
• Page End: 27
• Publication Date: 2015-01
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2014.10.016
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Thoracic failure after definitive chemoradiotherapy for NSCLC is common.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">PET may predict outcomes as well as the sites of disease progression.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">High patient MTV was associated with an increased risk of disease progression.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Progression nearly always occurred in lesions with high MTV.</p> </list-item> </list> </p> </sec> </abstract>